Bausch Health Companies Inc.
Approval Represents an Important Breakthrough in One of the Largest Medical Aesthetics Markets
(*CORRECTION to the release that was posted earlier on January 18, 2024: The TR-4 Return Pad is approved for use by the U.S. Food & Drug Administration (as part of the Thermage FLX device registration) See sentence below.*)
LAVAL, QC / ACCESSWIRE / January 18, 2024 / Bausch Health Companies Inc. (NYSE/TSX:BHC) and Solta Medical, a global leader in the medical aesthetics market, today announced the approval of Thermage® FLX and the TR-4 Return Pad by China's National Medical Products Administration (NMPA). [See *Correction above: The TR-4 Return Pad is not approved for use by the U.S. Food & Drug Administration.]
"The approval of Thermage FLX, and the TR-4 return pad, marks a significant milestone for Solta Medical," Thomas J. Appio, Bausch Health Chief Executive Officer, said. "Not only is this important for growing our business, but it also represents an enormous achievement for our R&D and Regulatory Teams, who worked tirelessly with the NMPA."
Thermage is a non-invasive treatment that uses radiofrequency technology to help tighten and improve the smoothness and texture of the skin's surface to optimize a patient's appearance. Thermage is a versatile and effective treatment that can be used on all skin types and genders, on a wide range of areas on the face, body and around the eyes. Globally, more than two million Thermage treatments have been performed.
"The approval from NMPA means we are able to continue the momentum of the growth of Thermage in China," Jiny Kim, Senior Vice President, Solta Medical, said. "Building on the legacy of Thermage CPT, which has been serving Chinese institutions and consumers effectively since 2015, we look forward to delivering the Thermage FLX proven technology to the Chinese market."
Indications
• The radiofrequency energy only delivery components of the Thermage® CPT and FLX system and accessories are indicated for use in:
o Non-invasive treatment of wrinkles around the eyes, including upper and lower eyelids
o Non-invasive treatment of wrinkles
• The simultaneous application of radiofrequency energy and skin vibration by the Thermage® CPT and FLX system and accessories are indicated for use in:
o Non-invasive treatment of wrinkles around the eye
o Non-invasive treatment of wrinkles
o Temporary improvement in the appearance of cellulite
Important Safety Information
- Do not undergo Thermage treatment if you have a cardiac pacemaker, a cardioverter, a defibrillator, or any other electrical implant. Let your doctor know if you have an electrical implant or if you have any questions about whether you should undergo a Thermage® treatment.
- Solta Medical has not studied the use of the Thermage system:
- Over skin fillers (lips, cheeks, facial wrinkles and skin folds)
- In people who are pregnant and/or breast feeding, diabetic, have an auto-immune disease such as lupus, have cold sores, have genital herpes, or have epilepsy
- In people who have permanent make-up and/or tattoos
- In children
- The most commonly reported adverse effect during treatment is mild to moderate pain in the area being treated.
- The most commonly reported adverse effects after treatment include the following:
- Mild redness may occur and typically resolves within 24 hours.
- Swelling may occur and typically resolves within 5 days but can remain up to several weeks.
- The following adverse effects occur infrequently:
- The procedure may produce heating in the upper layers of the skin, causing burns and subsequent blister and scab formation. There is a possibility of scar formation.
- Skin surface irregularities may appear up to 1 or more months post-treatment.
- Numbness, tingling" or temporary paralysis may occur; typically resolves in a short period of time but may persist up to several weeks.
- Lumps or nodules may occur under the skin primarily in the neck area, and usually resolve within 1 or 2 weeks without chronic or long-term complications.
- Skin may darken, but normally resolves within several months.
Ask your doctor for more information about Thermage FLX and see www.thermage.com for additional details.
About Solta Medical
Solta Medical, a business unit of Bausch Health, is a global leader in the medical aesthetics market. Our vision at Solta is to develop and support trusted aesthetic brands that provide value to our customers and their patients. The Thermage® RF systems, Fraxel® laser, Clear + Brilliant® laser, and VASER® ultrasonic system provide exceptional results for patients and lasting growth to physicians due to our foundation of brands that have stood the test of time. More than five million procedures have been performed with Solta Medical's portfolio of products around the world. More information can be found at www.solta.com.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX:BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership interest in Bausch +Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.
Forward-looking Statements
This news release may contain forward-looking statements about the future performance of Bausch Health, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions, including statements about the expected results of, and market for, the Company's Thermage® treatment. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.
SOURCE: Bausch Health Companies Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Traveler Care Launches Global Medical Dispatch Platform to Help Travel Insurance Companies Cut ER Claims by 80%4.8.2025 15:00:00 CEST | Press release
NEW YORK CITY, NY / ACCESS Newswire / August 4, 2025 / Traveler Care, a breakthrough medical dispatch platform that brings urgent care directly to travelers in hotels, Airbnbs, and vacation rentals, has officially launched worldwide - offering travel insurance companies a high-impact solution to reduce avoidable emergency room and hospital claims.Traveler care traveler.care home page A Concierge Alternative to the Emergency Room Traveler Care connects travel insurers and their policyholders to a network of licensed, on-call providers who visit travelers in their accommodations - typically within 60-90 minutes. Conditions such as flu, food poisoning, dehydration, allergic reactions, UTIs, sprains, and wound care are treated on-site, eliminating the need for an ER visit. "In most cases, travelers just need a doctor - not a hospital admission," said Eli Ofel, founder of Traveler Care. "We've built a scalable, insurer-ready solution that saves money and delivers a far better traveler exper
Rust Mobile Revealed With Official Trailer, First Hands-on Demo Set for Gamescom 20251.8.2025 18:30:00 CEST | Press release
The new cinematic trailer showcases Rust Mobile retaining the DNA of its PC predecessor, from cutthroat PvP to base raiding while offering the accessibility and flexibility of mobile Players can get a hands-on experience of Rust Mobile as it makes its debut at gamescom from 20th to 24th August Players are invited to pre-register at rustmobile.com SHENZHEN, CN / ACCESS Newswire / August 1, 2025 / Level Infinite is thrilled to reveal gameplay features for Rust Mobile, the officially licensed mobile adaptation of the iconic PC survival game Rust. Recreating the brutal survival experience, Rust Mobile combines the original with mobile-first innovations and will see its public hands-on debut at gamescom 2025.Rust Mobile Revealed Pre-registration is open now Watch the cinematic trailer here. Officially licensed by Facepunch Studios, Rust Mobile stays true to the uncompromising spirit of the original, delivering a survival experience fans know and love. From open-world exploration and ruthles
Innodata Reports Second Quarter 2025 Results with Revenue up 79% Year-Over-Year and Raises Full Year Guidance31.7.2025 22:15:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / July 31, 2025 / INNODATA INC. (Nasdaq:INOD) today reported results for the second quarter ended June 30, 2025. Revenue of $58.4 million, representing 79% year-over-year organic revenue growth. Adjusted EBITDA of $13.2 million, an increase of $10.4 million from $2.8 million in the same period last year.* Net income of $7.2 million, or $0.23 per basic share and $0.20 per diluted share, compared to a de minimis net loss, or $0.00 per basic and diluted share, in the same period last year. Cash, cash equivalents and short-term investments were $59.8 million as of June 30, 2025 and $46.9 million as of December 31, 2024. * Adjusted EBITDA is defined below. Jack Abuhoff, CEO, said, "Q2 was another outstanding quarter. We beat analysts' expectations across the board on key metrics - revenue, Adjusted EBITDA, net income, and fully-diluted EPS. As a result of strong demand and momentum, which includes significant new deal wins across a diversity of new and existin
Polaris Renewable Energy Announces Q2 2025 Results31.7.2025 14:00:00 CEST | Press release
TORONTO, ONTARIO / ACCESS Newswire / July 31, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the three and six months ended June 30, 2025. This earnings release should be read in conjunction with the Company's condensed consolidated interim financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. 2025 HIGHLIGHTS Second quarter consolidated energy production totaled 215,797 MWh, representing a 15% increase compared to 186,886 MWh in the same quarter last year. The increase is mainly attributable to stronger hydrological conditions in Peru and the contribution from the Puerto Rican wind farm, acquired on March 3, 2025, which did not contribute to consolidated energy production in t
Polaris Renewable Energy Declares Quarterly Dividend31.7.2025 14:00:00 CEST | Press release
TORONTO, ONTARIO / ACCESS Newswire / July 31, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on August 22nd to shareholders of record at the close of business on August 11th. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Company's ope
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom